Kathryn Lindley
Director
Bioanalytical Operations
BioAgilytix
Germany
Biography
Kathie has over 20 years of experience in academia and industry at UNC-Chapel Hill and GlaxoSmithKline. She has a wide range of experience in cell-based and immunoassay development utilizing platforms including ELISA, ELISpot, MSD, DELFIA, RIA and FMAT. Kathie is also an expert in the use and interpretation of BIAcore technology having developed high throughput primary antibody screens using the BIAcore A100. She has developed and holds patents on several monoclonal antibodies that are being progressed as therapeutic agents for sarcopenia, breast cancer, and osteoarthritis. Since coming to BioAgilytix Labs, Kathie has developed and validated biomarker and immunogenicity assays, both cell-based and plate-based, under GLP regulations. Additionally, she has published in peer-reviewed journals and been an invited speaker at national and international meetings. Kathie has a Bachelor’s degree from Meredith College and a Master’s degree in Microbiology and Immunology from UNC-Chapel Hill.
Research Interest
Microbiology and Immunology
